Therapeutic Human Polyclonals, Inc.
Therapeutic Human Polyclonals, Inc., (THP) was founded as a biotherapeutics company to develop a unique transgenic mammalian platform to create human antibodies. THP was the first company to create transgenic rabbits with a human antibody repertoire for producing both monoclonal and polyclonal antibody therapeutics.
Roche, the world’s largest biotechnology company, completed its acquisition of THP for $56.5 million in March 29, 2007.
Investors
Research Corporation Technologies and SangStat Medical Corp. (acquired by Genzyme Corporation in Cambridge, Mass.)
Inventors/Founders
- Roland Buelow, Ph.D.
- Wim van Schooten, Ph.D.